Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumour-bearing mice

Show simple item record

dc.contributor.author Wang, Limei
dc.contributor.author Pei, Jin
dc.contributor.author Cong, Zhongcheng
dc.contributor.author Zou, Yifang
dc.contributor.author Sun, Tianmeng
dc.contributor.author Davitt, Fionán
dc.contributor.author Garcia-Gil, Adrià
dc.contributor.author Holmes, Justin D.
dc.contributor.author O'Driscoll, Caitríona M.
dc.contributor.author Rahme, Kamil
dc.contributor.author Guo, Jianfeng
dc.date.accessioned 2019-04-05T10:12:31Z
dc.date.available 2019-04-05T10:12:31Z
dc.date.issued 2019-03-08
dc.identifier.citation Wang, L., Pei, J., Cong, Z., Zou, Y., Sun, T., Davitt, F., Garcia-Gil, A., Holmes, J. D., O' Driscoll, C. M., Rahme, K. and Guo, J. (2019) 'Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumour-bearing mice', International Journal of Nanomedicine, 14, pp. 1817-1833. doi: 10.2147/IJN.S192520 en
dc.identifier.volume 14 en
dc.identifier.startpage 1817 en
dc.identifier.endpage 1833 en
dc.identifier.issn 1176-9114
dc.identifier.uri http://hdl.handle.net/10468/7718
dc.identifier.doi 10.2147/IJN.S192520 en
dc.description.abstract Background: Gold nanorods (AuNRs), due to the optical and electronic properties namely the surface plasma resonance, have been developed to achieve the light-mediated photothermal therapy (PTT) for cancer. However, PTT alone may suffer from inefficient tumor killing. Recently, the combination of PTT and chemotherapy has been utilized to achieve synergistic anticancer effects. Methods: In this study, AuNRs capped with hexadecyltrimethylammonium bromide (CTAB), poly(acrylic acid) (PAA), and PEGylated anisamide (a ligand known to target the sigma receptor) have been developed to produce a range of negatively charged anisamide-targeted PEGylated AuNRs (namely Au-CTAB-PAA-PEG-AA) for the combination of PTT and chemotherapy (termed as chemo-photothermal therapy [CPTT]). Epirubicin (EPI, an anthracycline drug) was efficiently loaded onto the surface of Au800-CTAB-PAA-PEG-AA via the electrostatic interaction forming Au800-CTAB-PAA-PEG-AA.EPI complex. Results: The resultant complex demonstrated pH-dependent drug release, facilitated nucleus trafficking of EPI, and induced antiproliferative effects in human prostate cancer PC-3 cells. When Au800-CTAB-PAA-PEG-AA.EPI complex was further stimulated with desired laser irradiation, the synergistic outcome was evident in PC-3 xenograft mice. Conclusion: These results demonstrate a promising strategy for clinical application of CPTT in cancer. en
dc.description.sponsorship Department of Science and Technology of Jilin Province, China (Outstanding Youth Foundation (20170520046JH)); Jilin University (Start-Up Research Grant Program (451170301168, 451160102052, 419080500667)); Central Universities, China (Fundamental Research Funds) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Dove Press en
dc.relation.uri https://www.dovepress.com/development-of-anisamide-targeted-pegylated-gold-nanorods-to-deliver-e-peer-reviewed-article-IJN
dc.rights © 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php) en
dc.rights.uri http://creativecommons.org/licenses/by-nc/3.0/ en
dc.subject Gold nanoparticles en
dc.subject Non-viral drug delivery en
dc.subject Chemotherapy en
dc.subject Photothermal therapy en
dc.subject Synergistic effect en
dc.title Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumour-bearing mice en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Justin D. Holmes, Chemistry, University College Cork, Cork, Ireland. +353-21-490-3000 Email: j.holmes@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2019-04-01T13:14:44Z
dc.description.version Published Version en
dc.internal.rssid 479925054
dc.contributor.funder Department of Science and Technology of Jilin Province en
dc.contributor.funder Jilin University en
dc.description.status Peer reviewed en
dc.identifier.journaltitle International Journal of Nanomedicine en
dc.internal.copyrightchecked No
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress j.holmes@ucc.ie en
dc.identifier.eissn 1178-2013


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php) Except where otherwise noted, this item's license is described as © 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement